Navigation Links
Antibody treatment protects monkeys from Hendra virus disease
Date:10/19/2011

A human antibody given to monkeys infected with the deadly Hendra virus completely protected them from disease, according to a study published by National Institutes of Health (NIH) scientists and their collaborators. Hendra and the closely related Nipah virus, both rare viruses that are part of the NIH biodefense research program, target the lungs and brain and have human case fatality rates of 60 percent and more than 75 percent, respectively. These diseases in monkeys mirror what happens in humans, and the study results are cause for hope that the antibody, named m102.4, ultimately may be developed into a possible treatment for people who become infected with these viruses.

In May 2010, shortly after the NIH study in monkeys successfully concluded, Australian health officials requested m102.4 for emergency use in a woman and her 12-year-old daughter. They had been exposed to Hendra virus from an ill horse that ultimately was euthanized. Both the woman and child survived and showed no side effects from the treatment.

"This is an important research advance that illustrates how scientific discoveries emerge through a steady stepwise process, and how our investment in research on countermeasures for biodefense and emerging infectious diseases can help global preparedness efforts," said Anthony S. Fauci, M.D., director of the NIH's National Institute of Allergy and Infectious Diseases (NIAID).

Hendra virus emerged in 1994 in Australia and primarily affects horses, which can spread the disease to humans. No person-to-person transmission of Hendra has been reported. Nipah virus emerged in 1998 in Malaysia, and also has been found in Bangladesh and India. Nipah appears to infect humans more easily than Hendra and can be transmitted from person to person.

The NIAID-supported study, which appears online in Science Translational Medicine, involved infecting 14 African green monkeys with a lethal dose of Hendra virus. Twelve of the monkeys then received two treatments with m102.4, one either at 10, 24, or 72 hours after being infected, and another 48 hours later. All 12 monkeys treated with the antibody survived. The two untreated control monkeys died eight days after being infected.

The findings are the result of a series of studies carried out by different research laboratories. A group from NIH's National Cancer Institute and the Uniformed Services University of the Health Sciences (USUHS) discovered m102.4 in 2006 and developed the antibody for use in laboratory research. USUHS and Australian collaborators then developed an animal study model of m102.4 in ferrets infected with Nipah virus; the University of Texas Medical Branch and USUHS developed a monkey study model of Hendra and Nipah infection; and together with investigators from Boston University and NIAID's Rocky Mountain Laboratories (RML) designed and carried out the antibody trial in biosafety level-4 (BSL-4) laboratory space at RML. Because the Hendra and Nipah viruses are so deadly and there is no licensed vaccine or treatment for either of them, both viruses must be studied in maximum-containment BSL-4 laboratories.

The World Health Organization reports 475 human cases of Nipah through 2008, with 251 deaths. Through the same period, there have been seven human Hendra cases with four fatalities. There also have been many horse fatalities. In their study, the scientists cite a handful of other outbreaks of Hendra virus in horses since 2008. Since June 2011, there have been 18 outbreaks in Australia, primarily in Queensland and New South Wales, with the latest reported Oct. 10.

Both viruses are spread by fruit bats, commonly known as flying foxes, which are reservoirs for these viruses. The fruit bats, which are resistant to the diseases, are found primarily in Australia but have been found as far west as Africa, north to India and Pakistan, and east to the Philippines.

Additional studies on m102.4 as a possible treatment and as a preventive vaccine for Nipah and Hendra virus infections are being planned.


'/>"/>

Contact: Ken Pekoc
kpekoc@niaid.nih.gov
301-402-1663
NIH/National Institute of Allergy and Infectious Diseases
Source:Eurekalert  

Related medicine news :

1. Blood Antibody May Signal Start of Ovarian Cancer
2. Specialized regulatory T cell stifles antibody production centers
3. Antibody Finding Might Help in Search for HIV Vaccine
4. Disorderly enzyme is key for antibody diversity
5. Combination antibody therapy shows promise in metastatic melanoma
6. Antibody-guided drug works against acute lymphoblastic leukemia
7. Antibody production gets confused during long-term spaceflight
8. Tiny antibody fragments raised in camels find drug targets in human breast cancer cells
9. Tufts receives patent for antibody treatment against hemolytic uremic syndrome
10. HJF signs distribution agreement for antibody to evaluate prostate cancer
11. Antibody Linked to Allergies on the Rise
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Antibody treatment protects monkeys from Hendra virus disease
(Date:4/24/2017)... , ... April 24, 2017 , ... Sean Fay is ... Space Bag, Sonicare Toothbrush, Juiceman Juicer, and the George Foreman Grill (which sold more ... other marketer in the last 25 years. , Now, due to changes in the ...
(Date:4/24/2017)... ... April 24, 2017 , ... The John P. McGovern Museum ... allows anyone, anywhere to track their cognitive health, and share results with their physicians. ... brain health on the museum's website. , BrainCheck founder, Dr. David Eagleman, formerly at ...
(Date:4/24/2017)... Virginia (PRWEB) , ... April 24, 2017 , ... ... announced that they are seeking public support to bring their novel lifesaving device ... appearance, wearable device packed with medical-grade sensors, specially designed to read a child’s ...
(Date:4/24/2017)... and Waycross, Ga. (PRWEB) , ... April 24, ... ... leader and trusted advisor within the telehealth industry, announces the company’s VideoMedicine mobile ... board-certified primary care providers. Available 24 hours a day, Quick Care provides patients ...
(Date:4/24/2017)... ... April 24, 2017 , ... According to the U.S. Centers ... the lives of 62 Americans each day.(1) Yet since 2011, the Drug Enforcement ... and prescribers by more than half.(2) Novus Medical Detox Center , a ...
Breaking Medicine News(10 mins):
(Date:4/19/2017)... DIEGO , April 19, 2017  Sorrento ... an antibody-centric, clinical-stage biopharmaceutical company developing new treatments ... announced the closing of its previously announced underwritten ... stock at a public offering price of $2.00 ... and estimated offering expenses payable by Sorrento.  The ...
(Date:4/19/2017)... Calif. , April 19, 2017  SARES•REGIS ... buildings it is developing at Conejo Spectrum Business ... , to Atara Biotherapeutics, Inc. , a ... severe and life-threatening diseases that have been underserved ... allogeneic T-cell therapies for cancer, autoimmune and infectious ...
(Date:4/18/2017)... DUBLIN , April 18, 2017 Research ... Devices Market 2017-2021" report to their offering. ... The global arthroscopy devices market to grow at ... The report, Global Arthroscopy Devices Market 2017-2021, has been prepared based ... report covers the market landscape and its growth prospects over the ...
Breaking Medicine Technology: